Joël A. G. van Roon

Utrecht University — Netherlands

Medicine · Health Sciences

45h-index5.1kcitations117works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Salivary Gland Disorders and Functions(38), Systemic Lupus Erythematosus Research(24), T-cell and B-cell Immunology(21), Rheumatoid Arthritis Research and Therapies(19), Immunotherapy and Immune Responses(12)

Publications117 total

Soluble IFNAR1 is linked to systemic and patient-reported outcomes, and emerges as a potential key regulator and predictive biomarker in Sjögren’s disease 3522
The Journal of Immunology·2025Open Access
Type II interferon-associated proteins in Sjogren’s disease: potential novel indicators for disease monitoring and predicting response to leflunomide and hydroxychloroquine therapy 3517
The Journal of Immunology·2025Open Access
Proteins linked to type II interferon response in Sjögren’s disease: novel indicators for disease monitoring and predicting treatment response to leflunomide and hydroxychloroquine combination therapy
Frontiers in Immunology·2025· 1 citedOpen Access
Lidocaine-induced tear production in primary Sjögren’s disease: neurologically induced lacrimation to broaden the horizon for treatment of ocular dryness?
Annals of the Rheumatic Diseases·2025
Primary Sjögren’s Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)
Annals of the Rheumatic Diseases·2025· 6 citedOpen Access
Molecular and spatial analysis of tertiary lymphoid structures in Sjogren’s syndrome
Nature Communications·2025· 26 citedOpen Access
Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjögren's disease
Clinical Immunology·2024· 2 cited
CCR9/CXCR5 Co-Expressing CD4 T Cells Are Increased in Primary Sjögren’s Syndrome and Are Enriched in PD-1/ICOS-Expressing Effector T Cells
International Journal of Molecular Sciences·2023· 11 citedOpen Access
Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjogren's disease
2023Open Access
In patients with primary Sjögren’s syndrome innate-like MAIT cells display upregulated IL-7R, IFN-γ, and IL-21 expression and have increased proportions of CCR9 and CXCR5-expressing cells
Frontiers in Immunology·2022· 15 citedOpen Access
Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype
Frontiers in Immunology·2022· 22 citedOpen Access
CCL5 Release by CCR9+ CD8 T Cells: A Potential Contributor to Immunopathology of Primary Sjögren’s Syndrome
Frontiers in Immunology·2022· 18 citedOpen Access
The Role of Interleukin-4 and Interleukin-10 in Osteoarthritic Joint Disease: A Systematic Narrative Review
Cartilage·2022· 42 citedOpen Access
Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary Sjögren’s syndrome
Lara D. Veeken·2022· 40 citedOpen Access
CXCL4 drives fibrosis by promoting several key cellular and molecular processes
Cell Reports·2022· 71 citedOpen Access
Addressing the clinical unmet needs in primary Sjögren’s Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts
Computational and Structural Biotechnology Journal·2022· 23 citedOpen Access
The Transcriptomic Profile of Monocytes from Patients With Sjögren’s Syndrome Is Associated With Inflammatory Parameters and Is Mimicked by Circulating Mediators
Frontiers in Immunology·2021· 23 citedOpen Access
Transcriptome Analysis of CCR9+ T Helper Cells From Primary Sjögren’s Syndrome Patients Identifies CCL5 as a Novel Effector Molecule
Frontiers in Immunology·2021· 14 citedOpen Access
Implication of miR-126 and miR-139-5p in Plasmacytoid Dendritic Cell Dysregulation in Systemic Sclerosis
Journal of Clinical Medicine·2021· 32 citedOpen Access
Autoantigen <i>TRIM21</i>/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity
RMD Open·2020· 22 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

J. W. J. Bijlsma(18), Floris P. J. G. Lafeber(14), Timothy R. D. J. Radstake(14), Aike A. Kruize(8), Lucas L. van den Hoogen(8), F.P.J.G. Lafeber(7), Sarita A. Y. Hartgring(7), Ruth Fritsch‐Stork(6), Cornelis P. J. Bekker(6), Alsya J. Affandi(6), Marzia Rossato(6), Ana P. Lopes(6), Kim M. G. Jacobs(5), Jan G. J. van de Winkel(5), Maarten R. Hillen(5), Sandra C. Silva‐Cardoso(5), Jorre S. Mertens(4), Siska Wijngaarden(4), Marta Cossu(4), Catharina G. K. Wichers(4)